Smallpox, RNA, Vaccination, Messenger RNA, Vaccine, Immune system
GSK joins forces with CureVac to manufacture its Covid-19 vaccine — and to develop another
GSK teams up with CureVac on Covid-19 vaccines.
Number you didn’t want to see here: 2022.
By @HelenBranswell https://t.co/nIR8FnkbYf
OpenThe pharma giant will partner with the smaller German company to help manufacture its mRNA vaccine — and jointly develop a separate vaccine.
GSK teams up with CureVac on Covid-19 vaccines.
Number you didn’t want to see here: 2022.
By @HelenBranswell https://t.co/nIR8FnkbYf
OpenGSK joins forces with CureVac to manufacture its Covid-19 vaccine — and to develop another
The pharma giant will partner with the smaller German company to help manufacture its mRNA vaccine — and jointly develop a separate vaccine.
We are sorry, we could not find the related article
If you are curious about Biotech Essentials, the Influencers Review and Companies & Industries
Please click on:
Or signup to our newsletters
Other Essentials
AI Essentials
Robotics
Robotics
Ethics
Ethics
Research
Research
Applied Use Cases
Applied Use Cases
Marketing
Marketing
Healthcare
Healthcare
Cybersecurity
Cybersecurity
Pharma Companies Have To Hit A Bull's-Eye To Launch Coronavirus Vaccine In 2021
Biopharma companies like Moderna and Johnson & Johnson are speeding ahead to develop a coronavirus vaccine. But don't bet on a vaccine launching in 2021.
Hopes of a coronavirus vaccine mount as three key biotech players make progress
Dozens of companies and public labs around the world are working to develop a vaccine to prevent the spread of the flu-like virus.
Sanofi, GSK to supply vaccine doses to WHO-backed alliance
French drugmaker Sanofi <SASY.PA> and Britain's GlaxoSmithKline <GSK.L> will supply 200 million doses of their COVID-19 candidate vaccine to a global inoculation scheme backed by the World ...
A second COVID-19 vaccine just reported excellent results. What now?
Moderna announced its preliminary results for its early stage COVID-19 vaccine candidate which found the preventative medicine to be 94.5% effective. Here's what that means.
With hard cash from U.K., Imperial to kick-start next-gen COVID-19 vaccine trials this month
As the U.S., Germany and France start funneling more cash into their life sciences for a solution to the COVID-19 problem, the U.K. is following suit with a new type of vaccine.
Merck scraps Covid-19 vaccine programs after they fail to measure up on efficacy in another major setback in the global fight
After turning up late to the vaccine development game in the global fight against Covid-19, Merck is now making a quick exit. The pharma giant is reporting this morning that it’s decided to ...
Hadassah research head raises questions about mRNA vaccine safety
Prof. Yossi Karko explains Israel’s vaccine candidate, questions efficacy of Russia’s Sputnik V
Novartis to Help Make Pfizer-BioNTech Covid-19 Vaccine
Novartis AG said Friday it will use manufacturing space to help make the Covid-19 vaccine from Pfizer Inc. and Germany’s BioNTech SE, with delivery of the shots coming as early as July. ...
Translate Bio, Sanofi secure CDMO capacity for potential COVID-19 mRNA vaccine
Sanofi has become the latest firm to leverage mRNA vaccine technology to tackle COVID-19. Its partner Translate Bio, meanwhile, has secured dedicated manufacturing capacity at AMRI to ...
CureVac’s IPO Hauls In $213M as Key mRNA COVID-19 Vaccine Test Nears
CureVac is playing catch-up to its messenger RNA (mRNA) peers in the race to develop a COVID-19 vaccine, but the company contends its technology could
Moderna and BioNTech – who are they?
Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. Just who are these companies and who is behind them, ...
Sanofi, GSK, racing to catch up, begin first human study of coronavirus vaccine
The two vaccine developers are betting their proven technology will lead to a more potent shot than others, making up for their slower pace of testing.
FDA Authorizes Moderna’s COVID-19 Vaccine in the US
The VRBPAC voted 20-0 with 1 abstention to support the benefit-risk profile associated with mRNA-1273.
Building a vaccine: how advanced are scientists in this global race?
With COVID-19 infections approaching 20 million worldwide, the search for a vaccine is gathering pace.
Sanofi and GSK move Covid-19 vaccine into human trials
Sanofi and GSK are joining the ranks of Covid-19 vaccine makers testing their candidates in people, launching a large Phase 1/2 clinical trial.
Where is the world at with a coronavirus vaccine?
There are 44 vaccines currently being evaluated for eventual use against coronavirus, with two of them at the clinical trial stage already. But the path ahead is still very long
GSK and CureVac announce strategic mRNA technology collaboration
Companies to collaborate on mRNA vaccine and monoclonal antibody research programmes in infectious diseases
Here’s what comes next for Moderna’s COVID-19 vaccine — if everything goes right
As the Cambridge biotech readies to launch a clinical trial involving 30,000 people, it will have to deal with the many complications that have undone countless experimental medicines.
Development of new coronavirus vaccines may be hitting critical mass. Here's how they work
Data on vaccines being tested by Johnson & Johnson and Novavax came out last week, and makers of AstraZeneca's vaccine and Russia's Sputnik V vaccine published some long-awaited details ...
Authorization of Moderna vaccine expands access in battle against COVID-19
Moderna's vaccine is reportedly more than 94% effective, and unlike Pfizer's vaccine, which must be shipped and stored at ultra-cold temperatures, can be kept at standard freezer ...